Oncogenic signaling

Current Opinion in Oncology

Volumn 8, Issue 1, 1996, Pages 54-59

  Jones, Cindy L A ^b   Kane, Madeleine A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BRYOSTATIN; CELL ADHESION MOLECULE; CYCLIC AMP; CYTOTOXIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RIBOZYME; SERPENTINE; SURAMIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

CANCER INHIBITION; CARCINOGENESIS; CELL DIVISION; DRUG CONJUGATION; GENE MUTATION; GENE THERAPY; HETEROZYGOSITY; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0029974511     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199601000-00010     Document Type: Review

References (67)

1. Powis G: Signalling pathways as targets for anticancer drug development. Pharmacol Ther 1994, 62:57-95.
2. Hollywood D: Signal transduction. Br Med Bull 1991, 47:99-115.
3. Jans DA: Nuclear signaling pathways for polypeptide ligands and their membrane receptors? FASEB J 1994, 8:841-847. This is a succinct but thorough review of how nuclear localization sequences in ligands, receptors, and other cell surface proteins may result in these molecules or fragments of them serving as transcription factors themselves.
4. Silver BJ: Platelet-derived growth factor in human malignancy. Biofactors 1992, 3:217-227.
5. Barnard JA, Beauchamp RD, Russel WE, Bubois RN, Coffey RJ: Epidermal growth factor related peptides and their relevance to gastrointestinal pathophyslology. Gastroenterology 1995, 108:564-580.
6. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna J: Bombesin like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985, 316:823-826.
7. Leslie KK, Tasset DM, Horwitz KB: Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am J Obstet Gynecol 1992, 166:1053-1061.
8. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI: The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994, 9:2109-2123.
9. Tuzi NL, Gullick WJ: eph, The largest known family of putative growth factor receptors. Br J Cancer 1994, 69:417-421.
10. Kiyokawa E, Takai S, Tanaka M, Iwase T, Suzuki M, Xiang YY, Naito Y, Yamada K, Sugimura H, Kino I: Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994, 54:3645-3650. The full cDNA sequence of ERK, a new member of the receptor tyrosine kinase EPH family, is reported together with its chromosomal localization at 1p34-35 determined by fluorescent in situ hybridization. Expression of ERK mRNA was present in normal epithelial tissues and fetal, but not adult, brain. High levels of expression were observed in cell lines derived from epithelial cancers. A high percentage (75%) of gastric adenocarcinomas expressed high levels of ERK, with well-differentiated cancers expressing high levels more frequently than poorly differentiated.
11. Soans C, Holash J, Pasquale EB: Characterization of the expression of the cekB receptor-type tyrosine kinase during development and in tumor cell lines. Oncogene 1994, 9:3353-3361.
12. Andres AC, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A: Expression of two novel eph-related protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994, 9:1461-1467.
13. Rozengurt E: Bombesin stimulation of mitogenesis. Am Rev Respir Dis 1990, 142:211-215.
14. Guan KL: The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal 1994, 6:581-589.
15. Dumont JE, Jauniaux J-C, Roger PP: The cyclic AMP-mediated stimulation of cell proliferation. Trends Biol Chem 1989, 14:67-71.
16. Reincke M, Karl M, Travis W, Chrousos GP: No evidence for oncogenic mutations in guanine nucleotide binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab 1992, 77:1419-1422.
17. Gupta SK, Gallego C, Johnson GL: Mitogenic pathways regulated by G protein oncogenes. Mol Biol Cell 1992, 3:123-128.
18. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258:607-613.
19. McMahon SB, Monroe JG: Role of primary response genes in generating cellular responses to growth factors. FASEB J 1992, 6:2707-2715.
20. Bergh JCS: Gene amplification in human lung cancer. Am Rev Respir Dis 1990, 142:s20-s26.
21. Courtneidge SA: Protein tyrosine kinases, with emphasis on the src family. Semin Cancer Biol 1994, 5:239-246.
22. Juliano R: Signal transduction by integrins and its role in the regulation of tumor growth. Cancer Metastasis Rev 1994, 13:25-30.
23. Giroldi LA, Schalken JA: Decreased expression of the Intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 1993, 12:29-37.
24. Weinberg WA: Tumor suppressor genes. Science 1991, 254:1138-1146.
25. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, Minna JD, Gazdar AF, Kaye FJ: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994, 9:2441-2448.
26. Lane DP: The regulation of p53 function: Steiner award lecture. Int J Cancer 1994, 57:623-627.
27. Vogelstein B, Kinzler KW: Has the breast cancer gene been found? Cell 1994, 79:1-3.
28. Miyake S, Najai K, Yoshino K, Oto M, Endo M, Yuasa Y: Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res 1994, 54:3007-3010. Of 51 esophageal squamous cell carcinomas, 44 were informative and 10 of these exhibited LOH for the DCC gene. LOH was not observed in well-differentiated cancers and correlated with extent of lymph node involvement. LOH did not correlate with stage, but 44 of 49 patients had stage III or IV cancers.
29. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993, 9:138-141.
30. Kandle H, Seymore L, Bezwoda WR: Soluble c-erbB2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994, 70:813-818.
31. Yeatman TJ, Mao W, Karl RC, Djeu JY: Phospholipase C gamma 1 is present on the surface of human colorectal cancer cells. Biochem Biophys Res Comm 1994, 201:1043-1049.
32. Meltzer PS: MDM2 and p53: a question of balance. J Natl Cancer Inst 1994, 86:1265-1266.
33. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878. Although this is a review, it is extensive in the types and positions of mutations in the p53 gene and how this relates to various cancers and their epidemiology.
34. Prendergast GC, Gibbs JB: Ras regulatory interactions: novel targets for anti-cancer intervention. Bioessays 1994, 16:187-191.
35. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y: Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res 1994, 54:3007-3010. In a study of 51 cases of esophageal carcinomas, the frequency of deletions in the DCC gene was found to be associated with metastasis.
36. McKenzie SJ: Diagnostic utility of oncogenes and their products in human cancer. Biochim Biophys Acta 1991, 1072:193-214.
37. Chrysogelos SA, Dickson RB: EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 1994, 29:29-40.
38. Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, Kaklamanis L: Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994, 74(suppl3):1021-1025.
39. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer 1994, 74:2956-2963. Paraffin-embedded sections from 354 axillary lymph node-positive women treated with adjuvant chemotherapy for breast cancer (randomized trial 77-30-51 by Mayo-NCCTG) were semiquantitatively scored for c-erb B2 expression by immunohistochemistry. c-erb B2 expression was significantly correlated with degree of nodal involvement, higher nuclear grade, and estrogen receptor negativity. However, c-erb B2 was not found to be an independent predictor of disease-free or overall survival.
40. Tetu B: Prognostic significance of her-2/neu oncoproteln expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994, 73:2359-2365.
41. Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor In bladder cancer as related to established prognostic factors, oncoproteln (c-erbB2, p53) expression and long-term prognosis. Br J Cancer 1994, 69:1120-1125.
42. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Sopec JT, Clarkepearson DL, Bast RC, Berchuck A: Multivariable analysis of DNA ploidy, p53, and her-2/neu as prognostic factors In endometrial cancer. Cancer 1994, 73:2380-2385.
43. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiter E, Harbeck N, Becker K, Siewert JR, Harbeck N: Prognostic value of DNA ploidy and c-erbB2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994, 73:1785-1794.
44. Yu DH, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erbB2/neu Overexpresslon enhances metastatic potential of human lung cancer cells by Induction of metastasis-associated properties. Cancer Res 1994, 54:3260-3266.
45. Press MF, Pike MC, Hung G, Zhou JY, Ma YL, George J, Dietzband J, James W, Slamon DJ, Batsakis JG, Elnaggar AK: Amplification and overexpresslon of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994, 54:5675-5682.
46. Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF: K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994, 54:5811-5815.
47. Moerkerk P, Arends JW, van Driel M, deBruine A, deGoeij A, ten Kate J: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994, 54:3376-3378. Ras mutations were studied in Duke's colorectal tumors and found to be significantly different between nonmetastasized and metastasized tumors. These results imply that maybe metastatic tumors do not evolve from nonmetastatic tumors but instead arise independently.
48. Scambia G, Catozzi L, Panici PB, Ferrandina G, Almadori G, Paludetti G, Cadoni G, Distefano M, Piffanelli A, Mancuso S, Maurizi M: Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors. Cancer 1994, 69:995-999.
49. Roncalli M, Viale G, Grimelius L, Johansson H, Wilander E, Alfano RH, Springall D, Battezzati PM, Polak JM, Coggi G: Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer 1994, 74:134-141.
50. Sato K, Miyahara M, Saito T, Kobayashi M: c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. Eur J Cancer 1994, 30A:1113-1117.
51. Barrios C, Castresana JS, Falkmer UG, Rosendahl I, Kreicbergs A: c-myc Oncogene amplification and cytometric DNA ploidy pattern as prognostic factors in musculoskeletal neoplasms. Int J Cancer 1994, 58:781-786.
52. Matsunaga T, Shirasawa H, Tanabe M, Ohnuma N, Kawamura K, Etoh T, Takahashi H, Simizu B: Expression of neuronal src mRNA as a favorable marker and Inverse correlation to N-myc gene amplification in human neuroblastomas. Int J Cancer 1994, 58:793-798.
53. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M: Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994, 70:293-296.
54. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T: Alteration of p53 gene In ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 1994, 70:1191-1197.
55. Prat J, Oliva E, Lerma E, Vaquero M, Matiasguiu X: Uterine papillary serous adenocarcinoma: a 10-case study of p53 and c-erbB-2 expression and DNA content Cancer 1994, 74:1778-1783.
56. Sarbia M, Proschen R, Bouchard F, Haorstmann O, Willer R, Gabbert HE: p53 Protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994, 74:2218-2223.
57. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G: p53 Expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995, 75:87-93.
58. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M: p53 Protein and vimentin in invasive ductal NOS breast carcinoma: relationship with survival and sites of metastases. Eur J Cancer 1994, 30A:1527-1534.
59. Vesalainen SLB, Lipponen PK, Talja MT, Alhava EM, Syrjanen KJ: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer 1994, 58:303-308.
60. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M: Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994, 10:2922-2930.
61. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994, 84:3105-3112.
62. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuenca R, Cruz MA, Martinez B, Pezzella F, et al.: p53 And BCL-2 expression in high grade B-cell lymphomas: correlation with survival times. Br J Cancer 1994, 69:337-341.
63. Chi S-G, deVere-White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994, 86:926-933.
64. Gibbs JB, Oliff AL: Pharmaceutical research in molecular oncology. Cell 1994, 79:193-198.
65. Siegall CB: Targeted toxins as anticancer agents. Cancer 1994, 74:1006-1012. This review is an update of how cytotoxic proteins are being used to target specific tumors.
66. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony JJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyl transferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 1994, 91:9141-9145. RAS requires farnesylation for its translocation from its cytosolic site of synthesis to the plasma membrane. This report is an example of the use of specific targeting of this oncogene activation to inhibit growth of transformed cells in vivo in a nude mouse model. Because this class of pharmaceutical is already safely being used in patients for the treatment of hyperlipidemias, these agents may rapidly move into treatment studies for RAS-dependent cancers in humans.
67. Vile RG, Hart IR: In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993, 53:962-967.